Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry. Teresa Bernal , Ainhoa Fernández Moreno , Almudena de LaIglesia , Celina Benavente , Ana García-Noblejas , Daniel García Belmonte , Rosalía Riaza , Olga Salamero , Maria Angeles Foncillas , Alicia Roldán , Víctor Noriega Concepción , Laura Llorente González , Juan Miguel Bergua Burgués , Soraya Lorente de Uña , Gabriela Rodríguez-Macías , Adolfo de la Fuente Burguera , Maria José García Pérez , Jose Luis López-Lorenzo , Pilar Martínez , Concepción Aláez , Marta Callejas , Carmen Martínez-Chamorro , José Rifón Roca , Lourdes Amador Barciela , Armando V Mena Durán , Karoll Gómez Correcha , Esperanza Lavilla Rubira , María Luz Amigo , Ferran Vall-Llovera , Ana Garrido , María García-Fortes , Dunia de Miguel Llorente , Anastasia Aules Leonardo , Carlos Cervero , Rosa Coll Jordá , Manuel M Pérez-Encinas , Marta Polo Zarzuela , Angela Figuera , Guillermo Rad , David Martínez-Cuadrón , Pau Montesinos Cancer medicine（2023）
摘要
Larger post-authorization studies may provide evidence of the clinical benefits of CPX-351 for AML in the real-life setting.
更多 查看译文
关键词
acute myeloid leukemia, clinical observations, intensive chemotherapy, real-world
AI 理解论文
溯源树
样例
